All Pharma News
BMS wins FDA approval of $13B cardio drug mavacamten

BMS wins FDA approval of $13B cardio drug mavacamten
J. Gardner BIOPHARMADIVE
29 Apr 2022
Share Share
Evelo Biosciences names former Alnylam, MyoKardia CEOs as strategic advisors

Evelo Biosciences names former Alnylam, MyoKardia CEOs as strategic advisors
GLOBENEWSWIRE
21 Apr 2022
Share Share
Bristol Myers uncorks more winning data for blockbuster-potential heart drug

Bristol Myers uncorks more winning data for blockbuster-potential heart drug
Kyle Blankenship ENDPTS
16 Feb 2022
Share Share
FDA delays its decision on Bristol Myers` $13B heart drug another three months

FDA delays its decision on Bristol Myers` $13B heart drug another three months
N. DeFeudis ENDPTS
20 Nov 2021
Share Share
BMS` $13B MyoKardia heart drug gets along with beta blockers

BMS` $13B MyoKardia heart drug gets along with beta blockers
Annalee Armstrong FIERCEBIOTECH
13 Nov 2021
Share Share
A couple months ahead of PDUFA data, BMS rolls out long-term data for mavacamten

A couple months ahead of PDUFA data, BMS rolls out long-term data for mavacamten
N. DeFeudis ENDPTS
13 Nov 2021
Share Share
LianBio inks $325M IPO for pipeline with BMS, BridgeBio, Lyra

LianBio inks $325M IPO for pipeline with BMS, BridgeBio, Lyra
Kyle LaHucik FIERCEBIOTECH
01 Nov 2021
Share Share
MyoKardia`s clinical ops lead jumps ship to Esker

MyoKardia`s clinical ops lead jumps ship to Esker
Ben Adams FIERCEBIOTECH
20 Aug 2021
Share Share
EXPLORER-HCM Trial finds substantial health status improvements with mavacamten

EXPLORER-HCM Trial finds substantial health status improvements with mavacamten
PRWEB
20 May 2021
Share Share
FDA accepts Bristol Myers` pitch for former MyoKardia drug; Clovis` Rubraca aces

FDA accepts Bristol Myers` pitch for former MyoKardia drug; Clovis` Rubraca aces
Max Gelman ENDPTS
20 Mar 2021
Share Share